Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer

Summary

This randomized clinical trial studies enhanced quitline intervention in smoking cessation for patients with non-metastatic lung cancer. Stop-smoking plans suggested by doctors may help patients with early-stage cancer quit smoking

Conditions

• Limited Stage Small Cell Lung Cancer
• Recurrent Small Cell Lung Cancer
• Stage IA Non-small Cell Lung Cancer
• Stage IB Non-small Cell Lung Cancer
• Stage IIA Non-small Cell Lung Cancer
• Stage IIB Non-small Cell Lung Cancer
• Stage IIIA Non-small Cell Lung Cancer
• Stage IIIB Non-small Cell Lung Cancer
• Tobacco Use Disorder

Interventions

OTHER

questionnaire administration

Ancillary studies

PROCEDURE

quality-of-life assessment

Ancillary studies

OTHER

counseling intervention

Undergo counseling session

OTHER

internet-based intervention

Receive enhanced quitline intervention

BEHAVIORAL

telephone-based intervention

Receive enhanced quitline intervention

OTHER

educational intervention

Receive usual care plus

DRUG

nicotine replacement therapy

Receive nicotine replacement patches

OTHER

educational intervention

Receive enhanced quitline intervention

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Wake Forest University Health Sciences

  lead OTHER

Principal Investigators

• Kathryn Weaver · Wake Forest University Health Sciences

Study Design

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2011-01-31

Primary Completion

2012-01-31

Completion

2012-05-31

FDA Drug

Yes

Countries

• United States

Study Locations